BioProcess International USA West

CPhI Worldwide

The BPI West 2019 agenda is comprised of five phase-based tracks, designed to bring attendees working across multiple departments together to collectively share challenges and discuss the solutions needed to improve the speed, lower the cost and increase the quality/safety of biologics development.

Increase viable CHO cell density by supplementation with recombinant Insulin Human AF

CHO cells are one of the most widely used platforms for the production of biopharmaceuticals. Increased demand for safety and reliability has moved the standard for CHO cell culture media
from Serum to Serum free and further on to chemically defined media. UAB in collaboration with Novo Nordisk Pharmatech (world’s largest supplier of recombinant insulin) has shown
that addition of animal origin free insulin to three leading commercially available off-the-shelf chemically defined media resulted in significant increases in viable cell density. In addition to
this benefit insulin has been proven to aid in the expression of difficult to express proteins.

Read the full study

Read more about our Insulin Human AF or contact us.



Vanessa León

International Marketing Manager


Direct phone: +45 4042 6284